Moreover, EML4‐ALK expressing cells with various ALK mutations including L1196M show higher susceptibility to other ALK inhibitors such as ceritinib, brigatinib and lorlatinib, which are off‐label for ALK+ALCL, than alectinib[10]. The gene discussed is ALK; the disease is anaplastic large cell lymphoma.